Melinta Company Profile

What is the competitive landscape for MELINTA

MELINTA has five approved drugs.

There are sixteen US patents protecting MELINTA drugs.

There are one hundred and ninety-eight patent family members on MELINTA drugs in forty-two countries and twenty-nine supplementary protection certificates in seventeen countries.

Summary for Melinta

International Patents:	198
US Patents:	16
Tradenames:	4
Ingredients:	3
NDAs:	5
Patent Litigation for Melinta:	See patent lawsuits for Melinta

Drugs and US Patents for Melinta

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Melinta Therap	KIMYRSA	oritavancin diphosphate	POWDER;INTRAVENOUS	214155-001	Mar 12, 2021		RX	Yes	Yes	8,420,592
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017		RX	Yes	Yes	9,750,822		Y
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-004	Feb 5, 2001	AB	RX	Yes	No
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017		RX	Yes	Yes	8,252,813		Y
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017		RX	Yes	Yes
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017		RX	Yes	Yes	8,410,077		Y
Melinta Therap	KIMYRSA	oritavancin diphosphate	POWDER;INTRAVENOUS	214155-001	Mar 12, 2021		RX	Yes	Yes	9,649,352		Y	Y

Expired US Patents for Melinta

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-004	Feb 5, 2001	5,001,161*PED
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-003	Jan 10, 1992	3,876,802
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-001	Jan 10, 1992	3,998,790
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-002	Jan 10, 1992	4,957,745*PED
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017	8,648,093
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-003	Jan 10, 1992	4,957,745*PED
Melinta Therap	TOPROL-XL	metoprolol succinate	TABLET, EXTENDED RELEASE;ORAL	019962-002	Jan 10, 1992	3,998,790

International Patents for Melinta Drugs

Country	Patent Number	Estimated Expiration
Israel	208956
Japan	2012072160
China	105288650
Hungary	S2100004
Hungary	S1600039
Hong Kong	1219883
Japan	2010539193

Supplementary Protection Certificates for Melinta Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3214083	PA2021002,C3214083	Lithuania		PRODUCT NAME: DELAFLOKSACINAS ARBA JO DRUSKA AR ESTERIS, ISKAITANT DELAFLOKSACINO MEGLUMINA; REGISTRATION NO/DATE: EU/1/19/1393 20191216
2337575	1690041-7	Sweden		PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; FIRST MARKETING AUTHORIZATION NUMBER SE: EU/1/15/989, 2015-03-23
2337575	300834	Netherlands		PRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323
3214083	LUC00196	Luxembourg		PRODUCT NAME: DELAFLOXACINE OU UN DE SES SELS OU ESTERS, Y COMPRIS LA MEGLUMINE DE DELAFLOXACINE; AUTHORISATION NUMBER AND DATE: EU/1/19/1393 20191219
2337575	16C0039	France		PRODUCT NAME: ORITAVANCINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,TELS QUE LES SELS DIPHOSPHATES; REGISTRATION NO/DATE: EU/1/15/989 20150323
3214083	C20210002 00366	Estonia		PRODUCT NAME: DELAFLOKSATSIIN;REG NO/DATE: EU/1/19/1393 19.12.2019
2337575	C20160037	Finland		PRODUCT NAME: MIGALASTAAT;REG NO/DATE: EU/1/15/1082 31.05.2016

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Melinta
• Melinta Therap

Pharmaceutical Competitive Landscape Analysis: Melinta – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

What is Melinta’s Market Position?

Melinta Therapuetics Inc., founded in 2013 and headquartered in Lincolnwood, Illinois, specializes in developing and commercializing antibiotics targeting resistant pathogens. As of 2023, the company operates primarily within the anti-infective segment, focusing on hospital-acquired infections and complicated skin and soft tissue infections.

In the competitive landscape, Melinta ranks as a mid-tier player. Its revenues, approximately $120 million in 2022, place it behind industry leaders such as Pfizer, GSK, and Merck, but ahead of niche biotech firms focused solely on antimicrobial development. The firm's market share in the anti-infective segment remains modest, estimated at below 2% of the global antibiotic market.

How Does Melinta Position Itself in the Market?

Product Portfolio

Melinta’s portfolio centers on four key antibiotics:

Product	Indication	Status	Sales (2022)
Baxdela (delafloxacin)	Community-acquired bacterial pneumonia, skin infections	Approved in US, EU, and select markets	$24 million
Vabomere (meropenem-vaborbactam)	Complicated urinary tract infections (cUTIs), intra-abdominal infections	Approved in US; limited global presence	$89 million
Minocycline (generic and branded)	Various bacterial infections	Generic, available worldwide	N/A
Melinta pipeline (several candidates)	Emerging anti-infectives	Under development	N/A

Baxdela and Vabomere represent core revenue drivers, with Vabomere accounting for approximately 74% of sales in 2022.

Geographical Reach

Most sales occur in North America, driven by U.S. approvals and hospital relationships. Limited international market penetration, primarily due to regulatory and distribution challenges. The company’s strategy emphasizes expanding through partnerships and new indications.

Commercial Strategy

Melinta employs a direct sales force targeting hospitals and healthcare providers. The firm emphasizes clinical differentiation and stewardship programs, aiming for broader adoption in hospital settings. It maintains an active pipeline to diversify revenue streams beyond its current product suite.

What Are Melinta’s Strengths?

Focus on Resistant Infections

Melinta specializes in antibiotics targeting multidrug-resistant organisms, including carbapenem-resistant Enterobacteriaceae (CRE). Its antibiotics have unique mechanisms of action, such as the fluoroquinolone delafloxacin’s enhanced tissue penetration and activity against MRSA.

Niche Market Focus

The company operates in a niche space, less crowded than broad-spectrum antibiotics. This reduces competitive pressure, especially in hospital settings where resistance is a critical concern.

Recent Regulatory Advancements

Vabomere received FDA approval in 2017 and EU approval in 2021. Baxdela gained FDA approval in 2017 and EU approval in 2018, establishing regulatory credibility.

Pipeline Potential

Several candidates in early-stage development target infections caused by resistant pathogens. The pipeline aims to meet unmet medical needs, offering growth prospects if successful.

What Are the Strategic Challenges?

Limited Market Penetration

Market penetration remains low due to hospital formulary hurdles, competition from established antibacterials, and reluctance to switch therapies without extensive clinical data.

Patent Expirations and Generic Competition

Certain products face impending patent cliffs, especially Minocycline, which is predominantly generic, reducing Melinta’s control over pricing and margins.

Pricing and Reimbursement

Pricing pressures in hospital payers and variable reimbursement policies limit revenue growth potential.

R&D Funding Constraints

As a smaller firm, Melinta relies heavily on strategic partnerships and partnerships to fund pipeline development. Insufficient capital may slow research progress, especially for later-stage candidates.

How Does Melinta Compare to Competitors?

Company	Focus Area	Market Cap (2023)	Notable Products	Global Presence	R&D Investment (USD millions)
Melinta	Resistant bacterial infections	~$230 million	Baxdela, Vabomere	North America	$20
Pfizer	Broad anti-infective portfolio	$210 billion	Zithromax, Zavicefta	Global	$10,000+
Merck	Anti-infectives and vaccines	$223 billion	Isentress, Merrem	Global	$8,000+
GSK	Antibiotics & anti-infectives	$66 billion	Augmentin, Zevtera	Global	$4,000+

Melinta’s smaller size and specialized focus contrast with large pharmaceutical firms, which have extensive R&D budgets and broader portfolios. Competition from both large multinationals and emerging biotech firms focusing on novel antibiotics challenges Melinta’s future growth.

What Are Strategic Opportunities for Melinta?

Expanding Indications and Market Reach

Therapeutic expansion into indications like complicated intra-abdominal infections, osteomyelitis, and pediatric uses could boost revenues. International approvals, especially in emerging markets, offer growth avenues.

Acquisitions and Partnerships

Partnering with larger companies for co-marketing or licensing can accelerate market penetration and pipeline advancement. Acquisitions of smaller firms with complementary assets could expand the portfolio.

Focused R&D Investment

Accelerating development of next-generation antibiotics targeting resistant pathogens can create patentable innovations, supporting premium pricing and market exclusivity.

Digital and Stewardship Initiatives

Implementing advanced stewardship programs can improve usage efficiency, reducing resistance development and positioning Melinta as a responsible innovator.

Key Takeaways

• Melinta holds a niche position in the anti-infective market, primarily focused on resistant bacteria.
• Its revenues depend heavily on Vabomere, with limited global penetration.
• The company’s strengths include a targeted product portfolio and regulatory approvals in key markets.
• Challenges include limited market access, patent expirations, pricing pressures, and constrained R&D funding.
• Strategic expansion into new indications, international markets, and collaborative development offers growth potential.

Frequently Asked Questions

1. How significant is Melinta in the global antibiotic market?
Melinta accounts for less than 2% of the global antibiotic market, mainly serving hospital-acquired infections within North America.

2. What are the main drivers of Melinta’s revenue growth?
The primary driver is Vabomere, with potential growth from Baxdela and pipeline candidates targeting resistant infections.

3. Which competitors pose the greatest threat to Melinta?
Large pharma companies like Pfizer, Merck, and GSK dominate the anti-infective market and have broader portfolios and R&D resources.

4. What regulatory hurdles does Melinta face?
Expanding internationally requires additional regulatory approvals; pipeline candidates must undergo clinical trials to secure future approvals.

5. What is the outlook for Melinta’s pipeline?
While promising, pipeline success depends on clinical trial outcomes, regulatory approvals, and strategic partnerships to fund development.

---

References

[1] Melinta Therapeutics Inc. (2023). Annual Report. Retrieved from https://www.melintatherapeutics.com/investors/financial-information/

[2] EvaluatePharma (2023). Antibiotic Market Analysis. PricewaterhouseCoopers.

[3] U.S. Food and Drug Administration (2017). FDA approvals of Baxdela and Vabomere.

[4] European Medicines Agency (2021). Vabomere EU Marketing Authorization.